Key opinion leaders highlight the MS treatment landscape. Ryan Haumschild, PharmD, MS, MBA: Now that we’ve talked about the background of multiple sclerosis [MS] in detail, I think it’s important for ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

Neurologists have found in a recent study that common drugs to treat multiple sclerosis lead to modest health benefits but very high costs, according to a news release from Kirkland, Wash.-based ...

Scientists are testing a drug that may offer hope for reversing nerve damage in MS. MANICO/Getty Images When immune cells attack the myelin sheath, this causes inflammation and interrupts the passage ...

Scientists have used AI to identify two novel subtypes of multiple sclerosis (MS), which could offer new, targeted treatments for patients. MS affects around 2.8 million people across the world. It’s ...

Grace Miller was a 24-year-old law school student when she was diagnosed with multiple sclerosis. For years prior, she’d had ...

BTK inhibitor implementation for MS treatment is explored. Ryan Haumschild, PharmD, MS, MBA: Now if we could, let’s discuss the emerging role of Bruton tyrosine kinase inhibitors [BTKis] in multiple ...

Smoldering-associated worsening (SAW) of multiple sclerosis (MS) deserves a broader, more comprehensive approach to diagnosis, treatment, and research that goes beyond neurologists’ understanding of ...

"The observed differential effects of high-efficacy disease-modifying agents across sexes underscore the importance of sex-specific considerations in making treatment decisions to personalize care in ...

A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022. According to the study published in ...

Initiating treatment for multiple sclerosis (MS) within 6 months of the first symptoms is associated with a significantly lower risk for severe disability one decade later, a new study suggests.